3% of the global population develops rheumatoid arthritis

Still, the 1st drug treatment fails to successfully achieve disease remission quickly after the diagnosis of rheumatoid arthritis.

 

For the last 40+ years low-dose methotrexate  has been the first-line treatment for patients that have been diagnosed with rheumatoid arthritis. For the patients that respond to the treatment, methotrexate is a safe, effective and reliable drug that can help patients to manage their disease for many years. However, in up to 60% of the patients, treatment with methotrexate alone is not sufficiently effective to suppress rheumatoid arthritis. These patients need additional 2nd line drugs to manage their disease.

Adding 2nd line rheumatoid arthritis treatments, such as TNF-alpha inhibitors, JAK inhibitors and IL-6 inhibitors, to methotrexate, does not only increases risks of adverse effects, it also strongly increases treatment costs.

 

Enter: NovoBioJect

 

Amplio Pharma is developing NovoBioJect, a novel, methotrexate-based product, designed to provide faster and durable efficacy in the majority of rheumatoid arthritis patients.